<DOC>
	<DOCNO>NCT02047604</DOCNO>
	<brief_summary>A Study Evaluate Safety , Pharmacokinetics , Pharmacodynamics , Efficacy Escalating Doses SAN-300 Patients Active Rheumatoid Arthritis Inadequate Response Disease-Modifying Anti-rheumatic Drug ( ) .</brief_summary>
	<brief_title>( C2013-0302 ) Safety Efficacy Escalating Doses SAN-300 Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>1 . Diagnosed RA ≥ 6 month accord American College Rheumatology ( ACR ) /European League Against Rheumatism ( EULAR ) Classification Criteria 2010 2 . 18 75 year age , inclusive , time informed consent 3 . Swollen joint count ≥ 6 ( 66joint count ) tender joint count ≥ 6 ( 68joint count ) Screening randomization 4 . Inadequate response therapy discontinuation therapy unacceptable toxicity least one prior traditional biologic diseasemodifying antirheumatic drug ( DMARD ) 5 . Stable dose methotrexate ( ≥ 15 mg/week ≤ 25 mg/week ) ≥ 6 week randomization 1 . Functional Class IV define ACR classification functional status RA 2 . History significant systemic involvement secondary RA ( e.g. , vasculitis , pulmonary fibrosis , Felty 's syndrome ) 3 . History malignancy carcinoma situ within 5 year Screening history melanoma . Patients history excise adequately treated nonmelanoma skin cancer eligible 4 . Evidence clinically significant uncontrolled concurrent disease cardiovascular , endocrinologic , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal , and/or major disease 5 . History recurrent clinically significant infection 6 . Current active infection serious local infection ( e.g. , cellulitis , abscess ) systemic infection ( e.g. , pneumonia , septicemia ) within 3 month randomization 7 . History severe allergic anaphylactic reaction biologic agent 8 . History allergy murine protein 9 . Surgery within 3 month randomization ( minor cosmetic surgery minor dental procedure ) plan surgical procedure Treatment Period Followup Period 10 . History tuberculosis latent infection currently undergo treatment 11 . History malaria 12 . Treatment regimen prednisone either 10 mg/day ( equivalent dose another corticosteroid ) take stable dose ≤ 10 mg/day least 4 week randomization 13 . Intraarticular corticosteroid injection ( ) within 4 week randomization 14 . Any live immunization/vaccination , include Herpes zoster , within 4 week randomization . Live vaccination must also avoid throughout study 15 . Abnormal laboratory value Screening Day 1 consider clinically significant 16 . Positive hepatitis C virus ( HCV ) antibody hepatitis B surface antigen ( HBsAg ) 17 . Positive human immunodeficiency virus ( HIV ) antibody 18 . History tuberculosis positive QuantiFERON®TB Gold test ( QFT )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Phase 2a multiple ascend dose , Anti-Very Late Antigen-1</keyword>
</DOC>